|
Researchers at Children's Cancer Institute have discovered what could prove a new and improved way to treat the poor-prognosis blood cancer acute myeloid leukemia, or AML.
Unlike acute lymphoblastic leukemia, the most common childhood cancer, AML is notoriously difficult to cure, often proving resistant to standard treatments. The researchers have been investigating what they believe to be the root cause of treatment resistance — leukemia stem cells — and have now hit upon a new therapeutic approach that works by targeting these cells.
|